Volker Gerdts new leader for VIDO-InterVac

Posted on February 09, 2019


Following an international search, Dr. Volker Gerdts was selected as the new director and CEO of the University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac).

Gerdts, who served as VIDO-InterVac’s Associate Director of Research for the past 11 years, succeeds Dr. Andrew Potter as the organization's fifth director.

Gerdts has led numerous international projects, including a Grand Challenges in Global Health project funded by the Gates Foundation, and was integral in the development of two new animal vaccines. As director, he plans to advance VIDO-InterVac’s scientific excellence, international reputation and commercialization efforts in infectious disease research and vaccine development.

“VIDO-InterVac is a global leader,” Gerdts said. “With some of the best minds and most advanced infrastructure in the world, we have the opportunity to make VIDO-InterVac the world’s premier research institute for emerging diseases.”

He noted that the addition of the containment level 3 in 2011, and the scheduled completion of the pilot-scale vaccine manufacturing facility in 2020, VIDO-InterVac will soon be able to make and test vaccines for humans and animals truly enabling ‘solutions through research.’

Gerdts received a Doctor of Veterinary Medicine from Hanover Veterinary School in Germany and a PhD equivalent from the Federal Research Institute for Animal Health on the Island of Riems. He first came to Canada in 1998 as a post-doctoral fellow at VIDO-InterVac. He was hired as a research scientist in 2002 and became an associate director in 2007.

For more information about the new director and VIDO-InterVac please visit www.vido.org